{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:31:34Z","timestamp":1765438294538},"reference-count":38,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["30901375"],"award-info":[{"award-number":["30901375"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"crossref","award":["7102125"],"award-info":[{"award-number":["7102125"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.vaccine.2013.03.046","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T18:06:48Z","timestamp":1366135608000},"page":"2427-2432","source":"Crossref","is-referenced-by-count":13,"title":["Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors"],"prefix":"10.1016","volume":"31","author":[{"given":"Yun-Zhou","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Peng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huai-Jie","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Yuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.03.046_bib0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0968-0004(02)02177-1","article-title":"Botulinum and tetanus neurotoxins: structure, function and therapeutic utility","volume":"27","author":"Turton","year":"2002","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis","volume":"80","author":"Schiavo","year":"2000","journal-title":"Physiol Rev"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/DMP.0b013e318158c5fd","article-title":"Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities","volume":"1","author":"Dembek","year":"2007","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0020","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0025","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0300-9084(00)01173-1","article-title":"Development of vaccines for prevention of botulism","volume":"82","author":"Byrne","year":"2000","journal-title":"Biochimie"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0030","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.addr.2005.01.016","article-title":"Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology","volume":"57","author":"Middlebrook","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1615\/CritRevImmunol.v27.i4.20","article-title":"Botulinum neurotoxin vaccines: past, present, and future","volume":"27","author":"Smith","year":"2007","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0040","doi-asserted-by":"crossref","first-page":"D33","DOI":"10.1016\/j.vaccine.2009.08.059","article-title":"Botulism and vaccines for its prevention","volume":"27","author":"Smith","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0045","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1128\/IAI.63.7.2738-2742.1995","article-title":"Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli","volume":"63","author":"Clayton","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0050","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0264-410X(00)00155-9","article-title":"Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin","volume":"19","author":"Holley","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0055","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/IAI.71.5.2941-2944.2003","article-title":"Expression of Hc subunits from Clostridium botulinum type C and D and their evaluation as candidate vaccine antigens in mice","volume":"71","author":"Woodward","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0060","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.febslet.2004.06.094","article-title":"Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies","volume":"572","author":"Tavallaie","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0065","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1128\/IAI.73.10.6998-7005.2005","article-title":"Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E","volume":"73","author":"Baldwin","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0070","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/IAI.01893-06","article-title":"Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route","volume":"75","author":"Ravichandran","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0075","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/IAI.01025-07","article-title":"Subunit vaccine against the seven serotypes of botulism","volume":"76","author":"Baldwin","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0080","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1128\/CVI.00239-08","article-title":"Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine","volume":"15","author":"Yu","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0085","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1016\/j.vaccine.2009.07.021","article-title":"Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D","volume":"27","author":"Stahl","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0090","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.vaccine.2009.02.091","article-title":"The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate","volume":"27","author":"Yu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0095","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0041-0101(98)00146-9","article-title":"Development of recombinant vaccines for botulinum toxin","volume":"36","author":"Smith","year":"1998","journal-title":"Toxicon"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1006\/prep.2000.1200","article-title":"Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris","volume":"18","author":"Byrne","year":"2000","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0105","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.toxicon.2006.02.013","article-title":"Recombinant C fragment of botulinum neurotoxin serotype B (rBoNTB(Hc)) immune response and protection in the rhesus monkey","volume":"47","author":"Boles","year":"2006","journal-title":"Toxicon"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0110","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1016\/j.vaccine.2007.02.081","article-title":"Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins","volume":"25","author":"Webb","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0115","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0264-410X(99)00253-4","article-title":"Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A","volume":"18","author":"Clayton","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF02255918","article-title":"DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice","volume":"7","author":"Shyu","year":"2000","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0125","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1016\/S0264-410X(03)00260-3","article-title":"DNA vaccination protects against botulinum neurotoxin type F","volume":"21","author":"Bennett","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0130","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1016\/j.vaccine.2004.04.006","article-title":"Efficacy DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters","volume":"22","author":"Jathoul","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0135","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/IAI.69.9.5709-5715.2001","article-title":"Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system","volume":"69","author":"Lee","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0140","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1016\/j.vaccine.2006.06.004","article-title":"Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice","volume":"24","author":"Lee","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0145","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1016\/j.vaccine.2007.10.016","article-title":"Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A","volume":"25","author":"Yu","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0150","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1016\/j.vaccine.2009.08.022","article-title":"Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors","volume":"27","author":"Yu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clim.2010.07.005","article-title":"Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F","volume":"137","author":"Yu","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0160","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.biologicals.2010.08.001","article-title":"Enhanced potency of individual and bivalent DNA replicon vaccines or conventional DNA vaccines by formulation with aluminum phosphate","volume":"38","author":"Yu","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0165","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/S0264-410X(02)00157-3","article-title":"Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid","volume":"20","author":"Torii","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0170","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses","volume":"75","author":"Pushko","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/08923971003782327","article-title":"Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM\u2013CSF gene adjuvant","volume":"33","author":"Li","year":"2011","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0180","doi-asserted-by":"crossref","first-page":"13601","DOI":"10.1073\/pnas.0405557101","article-title":"A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores","volume":"101","author":"Hermanson","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/jiq017","article-title":"Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge","volume":"203","author":"Hirao","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.046_bib0190","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1073\/pnas.1013083107","article-title":"Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities","volume":"107","author":"Merkel","year":"2010","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13003927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13003927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T12:18:59Z","timestamp":1595679539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13003927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":38,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0264410X13003927"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.046","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}